Immuneering reported updated Phase 2a results for the MEK inhibitor atebimetinib combined with modified chemotherapy in first‑line pancreatic cancer, showing a 64% one‑year overall survival rate in the study cohort versus lower historical benchmarks. The company cited encouraging progression‑free survival separation and plans a pivotal randomized trial enrolling ~510 patients to test OS as the primary endpoint, with a first pivotal patient expected around mid‑2026. Management framed the Phase 2a update as robust enough to justify registrational planning; shares traded with notable volatility on the readout. Investors and analysts are focused on whether the survival signal will hold in randomized settings and how external benchmarks compare. Immuneering’s path underscores the challenge of translating promising early survival signals into definitive approvals and the financial stakes tied to moving into large OS‑driven pivotal trials.